Controlled-release PTH compound

US12295989B2 · kind B2 · utility

Assignee

• ASCENDIS PHARMA BONE DISEASES A/S · DK

Inventors

• Kennett Sprogøe · Rudegård, DK
• Guillaume Maitro · Mannheim, DE
• Mathias Krusch · Hirschhorn, DE
• Thomas Wegge · Heidelberg, DE
• Joachim Zettler · Heidelberg, DE
• Lars Holten-Andersen · Vanløse, DK
• David Karpf · Mountain View, US

Key dates

• Filing date: Jan 24, 2024
• Grant date: May 13, 2025
• Expiry date: Jan 24, 2044

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides a method of treating or controlling hypoparathyroidism in a human patient by administering to the human patient a pharmaceutical composition comprising a controlled-release PTH compound or a pharmaceutically acceptable salt thereof. The controlled-release PTH compound comprises a PTH moiety reversibly conjugated to a branched polyethylene glycol carrier. The composition is administered by subcutaneous injection no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered by subcutaneous injection at the same dosing frequency required to maintain a serum albumin-adjusted calcium level in serum of above 8.5 mg/dL over a 24 hour period.